Qbiotics, page-20

from 27 April 2020..................
QBiotics anticipates first launches to veterinary clinics across Europe from May 2020.
We are delighted to announce that STELFONTA® will be commercially available, with product being distributed
in Europe through our Virbac partners. This major milestone creates a repeatable revenue stream for QBiotics
and validates the company’s ability to develop, register and commercialise a pharmaceutical addressing
significant medical problems,” said QBiotics’ CEO and Managing Director, Dr Victoria Gordon.
“It has been an exciting time for the company, having received approval from both the European Medicines
Agency (EMA) and Veterinary Medicines Directorate (VMD) for STELFONTA® earlier this year. This regulatory
approval triggered our second milestone payment and revenue initiated by the first shipment of product to Virbac
for distribution to veterinary clinics across the European continent.” said Dr Gordon. ............